COMP <GO>
OCGN vs IPSC // RSI-14 & 200D SMA MOMENTUM
Ocugen Inc. (NASDAQ) VS. Century Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OCGN 0
— IPSC 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: IPSC
LAST: $0.74 (-4.15%) • MKT CAP: $252.4M
rsi-technicals
28.3
LAST: $1.46 (-2.67%) • MKT CAP: $264.4M
rsi-technicals
44.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCGN VS. IPSC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCGN | IPSC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -14.10% | -20.90 | IPSC | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -22.65% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -15.80% | -44.20 | IPSC | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -8.80% | -51.20 | IPSC | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 180.00% | -171.20 | IPSC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 28.3 | 44.7 | -16.44 | IPSC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $252.4M | $264.4M | -$12.0M | IPSC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCGN REV | IPSC REV | OCGN GROSS % | IPSC GROSS % | OCGN FCF | IPSC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.4M | $109.2M | — | — | -$57.1M | -$104.7M |
| FY 2024 | $4.1M | $6.6M | — | — | -$45.5M | -$110.3M |
| FY 2023 | $6.0M | $2.2M | — | — | -$62.1M | -$88.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCGN // BETA —
IPSC // BETA —